Safety of Rotavirus Vaccination in Infants That Were Exposed to Biologics In Utero: A Systematic Review
Inflammatory Bowel Diseases · 2025
DOI: 10.1093/ibd/izae220 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Trevor L Schell und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology & Hepatology, Department of Medicine, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA. Hauptthemen laut MEDLINE: Rotavirus Vaccines, Biological Products, Vaccination, Rotavirus Infections. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Background
In infants that were exposed to biologics in utero, gastroenterology societal guidelines have either recommended against administration of the live rotavirus vaccine until 6-12 months of age or until serum biologic levels are undetectable. We performed a systematic review to evaluate the safety of rotavirus vaccination in biologic-exposed infants.
Methods
EMBASE, PubMed, Scopus, and Cochrane databases were searched from 2006 to 2024 for original data reporting on the safety of rotavirus vaccination in infants that were exposed to anti-tumor necrosis factors (TNFs) (ie, infliximab, adalimumab, golimumab, certolizumab) and non-TNF biologics (ie, vedolizumab, ustekinumab, rizankizumab, mirikizumab) in utero.
Results
A database search yielded 7185 screening results of which 10 studies met inclusion criteria. There were over 300 instances of rotavirus vaccination in biologic-exposed infants (n = 162 exposed to anti-TNFs, n = 142 exposed to non-TNF biologics). Biologic-exposed infants were not at an increased risk of severe adverse events or adverse events of any severity related to rotavirus vaccination.
Conclusions
Administration of the live rotavirus vaccine appears to be safe in biologic-exposed infants. As such, with careful examination of the risks and benefits, there may be a role for rotavirus vaccination in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology & Hepatology, Department of Medicine, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
- Department of Medicine, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
- Department of Health Sciences Library, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
- Mayo Clinic, Division of Gastroenterology & Hepatology, Inflammatory Bowel Disease Center, Jacksonville, FL, USA.
- University of Wisconsin-Madison, School of Pharmacy, Madison, WI, USA.
ORCID-Profile: Trevor L Schell, Sumona Saha, Freddy Caldera
Zitieren
APA
Schell, T. L., Fass, L., Hitchcock, M. E., Farraye, F. A., Hayney, M. S., Saha, S., & Caldera, F. (2025). Safety of Rotavirus Vaccination in Infants That Were Exposed to Biologics In Utero: A Systematic Review. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae220
Vancouver
Schell TL, Fass L, Hitchcock ME, Farraye FA, Hayney MS, Saha S, et al. Safety of Rotavirus Vaccination in Infants That Were Exposed to Biologics In Utero: A Systematic Review. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izae220
BibTeX
@article{Schell2025,
author = {Schell, Trevor L and Fass, Lucas and Hitchcock, Mary E and Farraye, Francis A and Hayney, Mary S and Saha, Sumona and Caldera, Freddy},
title = {Safety of Rotavirus Vaccination in Infants That Were Exposed to Biologics In Utero: A Systematic Review},
journal = {Inflammatory Bowel Diseases},
year = {2025},
doi = {10.1093/ibd/izae220}
}
EUVIMED